Peptides for chronic fatigue syndrome FAQ

Reduce the dose by 50% and split into twice-daily administration. Dihexa's HGF receptor binding can trigger rapid synaptic remodeling that outpaces glial support cell adaptation. Manifesting as headaches, sensory sensitivity, or sleep disruption. A slower titration (starting at 0.25mg/kg and increasing weekly) allows astrocyte and oligodendrocyte populations to scale alongside neuronal changes. If symptoms persist below threshold dose, Dihexa may not be appropriate for that patient's current neural substrate.

Administer zinc picolinate (30mg daily) for two weeks before initiating Thymalin. Thymulin. The peptide hormone Thymalin helps restore. Requires zinc as a structural cofactor for receptor binding. Patients with serum zinc below 80 mcg/dL show blunted T-regulatory cell response and minimal IL-6 reduction even at standard Thymalin doses. The two-week saturation window allows hepatic zinc stores to normalize before introducing the thymic peptide.

Extend the protocol to eight weeks (20 sessions total) and verify NAD+ cofactor status. Mitochondrial biogenesis requires NAD+ as an electron carrier. Patients with depleted NAD+ pools (common in chronic illness) can't synthesize new mitochondria regardless of PGC-1α upregulation. Nicotinamide riboside (300mg daily) or NMN (500mg daily) supplementation addresses this substrate bottleneck. If no improvement occurs by session 20, mitochondrial dysfunction may not be the primary driver of cognitive symptoms.

Reassess whether immune dysregulation is the primary driver of your fatigue. Some CFS cases initially appear immune-dominant but are actually neurological or metabolic at the root. Elevated cytokines may be secondary to mitochondrial dysfunction or chronic stress signalling rather than primary immune failure. If Thymalin produces no cytokine normalisation after eight weeks at therapeutic dose, pivot to neuroprotective peptides like Cerebrolysin or metabolic peptides like MK-677. Continuing a non-responsive protocol beyond this window wastes time and delays identifying the correct mechanism.

This pattern suggests neurological recovery outpacing metabolic or mitochondrial repair. Add a growth hormone secretagogue (MK-677 or CJC-1295/Ipamorelin) to your existing neuroprotective peptide protocol. Cognitive function can improve through synaptic remodelling while cellular ATP production remains impaired. They operate on different timelines. Mitochondrial biogenesis takes 8–12 weeks, whereas synaptic plasticity changes occur within 4–6 weeks. The lag is expected and doesn't indicate protocol failure.

Start with comprehensive immune and metabolic panels before selecting a peptide protocol. Request cytokine profiling (IL-6, TNF-alpha, IL-1beta), lymphocyte subset analysis (CD4+/CD8+ ratios, NK cell activity), serum BDNF, and mitochondrial function markers (lactate-to-pyruvate ratio, ATP production in muscle biopsy if accessible). The testing cost ranges from $400–$1,200 depending on panel depth, but it prevents wasting months on peptides targeting the wrong pathway. Insurance rarely covers these as diagnostic tools for CFS, but functional medicine clinics and research-oriented physicians can order them.